Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50

Capricor Therapeutics Inc (NASDAQ:CAPR) has earned a consensus rating of “Buy” from the six research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $34.50.

A number of brokerages have weighed in on CAPR. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler began coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald upped their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its stake in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 84,350 shares during the period. Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the 2nd quarter valued at $426,000. Point72 Asset Management L.P. bought a new position in shares of Capricor Therapeutics during the 3rd quarter valued at $3,806,000. The Manufacturers Life Insurance Company purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth $161,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 15,872 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $14.08 on Thursday. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40. The stock has a market cap of $640.22 million, a PE ratio of -13.28 and a beta of 3.98. The business’s 50-day moving average price is $17.36 and its 200-day moving average price is $10.57.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.